Upstate Active Clinical Trials

Study Title:

NRG-GY028: A PHASE IB AND RANDOMIZED PHASE II TRIAL OF MEGESTROL ACETATE WITH OR WITHOUT IPATASERTIB IN
RECURRENT OR METASTATIC ENDOMETRIOID ENDOMETRIAL CANCER

What is the purpose of the study? (in Layman's terms, please describe the study)

Testing the addition of the AKT inhibitor, ipatasertib, to treatment with the hormonal agent megestrol acetate for recurrent or metastatic endometrial cancers – Phase II portion

Upstate Institutional Review Board (IRB) Number:

2171973

Study/Protocol ID:

NRG-GY028

Study Phase:

ll

Patient Age Group:

Adults

Principal Investigator:

Mary J Cunningham, MD

What is involved if I participate?

• How long is the study?
  5 years
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  CBC/Differential/Platelets. Chemistries (BUN, creatinine, sodium, potassium, chloride, CO2, calcium, glucose, total bilirubin, total protein, albumin, alkaline phosphatase, AST, ALT). Fasting glucose. Pregnancy test. CT scans. Misc. study related blood test.

Where will the study take place?

University Hospital Downtown Campus, Cancer Center, and Upstate GYN Oncology at Madison Irving.

Other Information:

PHASE II TRIAL OF MEGESTROL ACETATE WITH OR WITHOUT IPATASERTIB IN RECURRENT OR METASTATIC ENDOMETRIOID ENDOMETRIAL CANCER.

ClinicalTrials.Gov ID:

NCT05538897

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Sonia Masood
Phone: 315-464-8232
Email: [email protected]

Return to Previous Page || Search Again